Work

A propensity score-matched retrospective study on sacubitril/valsartan use and 6-month readmission rates in patients with acute heart failure

Year: 2025

Type: article

Abstract: Background Sacubitril/valsartan is a compound preparation commonly used for treating chronic heart failure with reduced ejection fraction. In clinical practice, it is also administered to patients with newly diagnosed acute heart failure. However, limited research exists on its benefits during hospitalization in this patient population. Aim To investigate the impact of in-hospital use of sacubitril/valsartan on the 6-month readmission rate in patients with newly diagnosed acute heart failure. Method A retrospective study was conducted involving 176 patients admitted for the first time with acute heart failure at Xiaoshan Hospital Affiliated to Hangzhou Normal University. Patients were divided into two groups based on whether they received sacubitril/valsartan during hospitalization: a treatment group and a control group. Clinical data were collected, and propensity score matching (PSM) was used to balance baseline characteristics. Logistic regression analysis was performed to evaluate the effect of sacubitril/valsartan on 6-month readmission. Results After PSM, 53 matched pairs were obtained, with balanced covariates between the two groups. Before matching, the readmission rate was 10.47% in the treatment group and 25.56% in the control group. Multivariate logistic regression indicated that sacubitril/valsartan was associated with a reduced risk of readmission (OR = 0.339, 95% CI [0.116–0.994], P = 0.049). However, after matching, the readmission rate was 13.21% in the treatment group and 20.75% in the control group. Logistic regression analysis post-matching showed no statistically significant reduction in readmission risk (OR = 0.728, 95% CI [0.212–2.496], P = 0.252). Conclusions In-hospital use of sacubitril/valsartan does not significantly reduce the risk of 6-month readmission in patients with newly diagnosed acute heart failure.

Source: PeerJ

DOI: 10.7717/peerj.20055

Authors: Lingdi Zhang, Qinglian Chen, Guofei Ren

Institution: Hangzhou Normal University

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,395